Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy Sensitivity in Platinum-Partial Sensitive Recurrent Ovarian Cancer
NCT04337632Phase 3Unknown
- Sponsor
- Hunan Cancer Hospital
- Start
- Aug 2017
- Primary completion
- Jun 2021
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pegylated liposomal doxorubicin in ovarian cancer (2 arms), sponsored by Hunan Cancer Hospital. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04337632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04337632.